Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: HRMY

Harmony Biosciences Holdings, Inc.

Healthcare | Biotechnology

No licensed closing price on file for HRMY. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$3.08

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:42 UTC.

What Harmony Biosciences Holdings, Inc. does

Harmony Biosciences is a neuroscience company developing treatments for rare neurological diseases including narcolepsy, epilepsy, and other sleep and neurological disorders. The company's lead product, WAKIX (pitolisant), is an FDA-approved treatment for excessive daytime sleepiness and cataplexy in narcolepsy patients and is the only approved narcolepsy treatment that is not a controlled substance.

Summarized from Harmony Biosciences Holdings, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$3.08
Return on equity18.24%
Debt/equity0.15

Revenue, margins & earnings

FY2021 Net income: $35MFY2021 Taxes & interest: $53MFY2021 Operating expenses: $162MFY2021 Cost of revenue: $56M$305MFY2021FY2022 Revenue: $438M — margin split not shown (non-operating gains)$438MFY2022FY2023 Net income: $129MFY2023 Taxes & interest: $63MFY2023 Operating expenses: $269MFY2023 Cost of revenue: $121M$582MFY2023FY2024 Net income: $145MFY2024 Taxes & interest: $45MFY2024 Operating expenses: $367MFY2024 Cost of revenue: $157M$715MFY2024FY2025 Net income: $159MFY2025 Taxes & interest: $50MFY2025 Operating expenses: $462MFY2025 Cost of revenue: $198M$868MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-18
  • 2026-09-18CHIEF MEDICAL OFFICERStock OptionOption exercise-900—
  • 2026-09-18CHIEF MEDICAL OFFICEROption exercise400$12.3K
  • 2026-09-18CHIEF MEDICAL OFFICEROption exercise900$27.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Harmony Biosciences Holdings, Inc. do?

Harmony Biosciences is a neuroscience company developing treatments for rare neurological diseases including narcolepsy, epilepsy, and other sleep and neurological disorders.

When did HRMY last file with the SEC?

Harmony Biosciences Holdings, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:42 UTC. This page is also available as JSON at /api/data?ticker=HRMY and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for HRMY and 5,000+ tickers.

Create a free account — keep HRMY
For your agent
GET /api/data?ticker=HRMY

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt